Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) (VitDBoneNF1)

Utah System of Higher Education (USHE)

Status and phase: Terminated; Phase 2

Conditions: Neurofibromatosis Type 1 (NF1)

Treatments: Drug: Cholecalciferol

Study type: Interventional

Funder types: Other; Other U.S. Federal agency

Identifiers

NCT01968590

DoD A-17236

W18XWH-12-1-0487 (Other Grant/Funding Number)

Details and patient eligibility

About

This clinical trial is conducted by one of 4 locations; University of British Columbia (Vancouver, CA), University of Utah (Salt Lake City, UT, USA), University of Cincinnati (Cincinnati, OH, USA), and University of Hamburg (Hamburg, Germany).

Adults with NF1 have a higher risk of osteopenia and osteoporosis, a condition of low bone density that can lead to fragile bones and bone breakage.

People with NF1 also have lower vitamin D levels than unaffected individuals. Vitamin D is important for normal bone health, but studies to improve bone health by vitamin D supplementation in people with NF1 have not been tried.

The purpose of this study is to treat adults with NF1 who have insufficient serum vitamin D levels with 2 different doses of vitamin D supplementation to determine if vitamin D supplementation ameliorates the usual loss of bone mineral density over 2 years.

Full description

Individuals with NF1 and vitamin D insufficiency will be supplemented with 2 different doses of cholecalciferol (vitamin D) to see if their loss of bone mineral density is lessened over time. It is important to study vitamins as carefully as one would study medications, even though vitamins are generally safer than medications. For this reason, a carefully controlled trial of two doses of vitamin D will be performed over a 2-year period. It will include controlled doses and safety checks for participants' health to be sure that the vitamin D supplementation is safe for people with NF1.

Two different doses of cholecalciferol, either 600 IU or 4,000 IU (IU means "International Units" a standard measure of the strength of the dose), will be used for supplementation. The trial is "double blind". This means that neither participant nor investigator team know which dose an individual participant might be randomized to receive until after the trial ends. In an emergency, however, the investigator can find out.

Participants will be randomized to one or the other dose, and each participant will be provided a bottle of liquid called "D-drops" with a dropper that automatically drops out a measured amount when the bottle is turned upside down.

Both doses of vitamin D, 600 IU and 4,000 IU, have been approved in the general population; however, it is possible that the bodies of people with NF1 handle vitamin D differently. Therefore, safety measures are assessed during this trial. Any new medical issues or concerns throughout the 2-year period will need to be recorded and assessed with the study team.

The primary measure of this study is bone mineral density obtained by bone densitometry (DXA) using low-dose xrays. Bone mineral density will be tested at the beginning and the end of the trial focusing on density of bones in the hip and spine. Secondary measures of this trial include questionnaires that measure quality of life and history of bone fractures.

When someone is insufficient in serum vitamin D and supplementation is recommended, it is also supplemented with calcium. Therefore, participants will be given a calcium supplement of 400 mg elemental calcium per day. A diary to keep daily track of vitamin D and calcium supplementation and documentation of fractures, should they occur, is provided.

Enrollment: 26 patients

Sex: All

Ages: 25 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

All individuals with NF1 (neurofibromatosis type 1), based on NIH diagnostic criteria, who are between the ages of 25 and 40 years, may participate in this study. All participants will be enrolled in the study and then screened for serum 25(OH)D levels, and all individuals with levels between 9 and 29ng/ml (inclusive) are eligible for vitamin D supplementation -

Exclusion criteria

1. diagnosis of Paget's disease, hyperthyroidism, hyperparathyroidism, or other medical condition that affects bone health
2. they foresee that they will be unable to comply with the two-year study protocol
3. Pregnant, planning to conceive within the next two years, or is less than 6 months post-delivery or lactation.
4. vitamin D supplementation in the last 3 months equal to or greater than 600IU per day
5. oral or IV glucocorticoid use for over 3 months
6. bisphosphonate therapy for more than 3 months
7. calcitonin therapy for more than 3 months
8. calcium supplementation in last 3 months equal to or greater than 1000mg per day
9. malignant peripheral nerve sheath tumor (MPNST)
10. history of kidney stones in last 5 years
11. individuals with metal instrumentation in spine or hip that preclude accurate DXA interpretation.
12. inability to obtain blood samples on routine venipuncture
13. anti-epileptic medical therapy
14. anticoagulant medical therapy

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

26 participants in 2 patient groups

cholecalciferol 600 IU

Active Comparator group

Description:

cholecalciferol in Ddrops form at either 600 International units per day versus 4,000 IU per day

Treatment:

Drug: Cholecalciferol

cholecalciferol 4,000 IU

Active Comparator group

Description:

Cholecalciferol at 4,000 IU per day in the form of liquid Ddrops

Treatment:

Drug: Cholecalciferol